Literature DB >> 19689861

Prevalence of pneumococcal polysaccharide vaccine administration and incidence of invasive pneumococcal disease in children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn screening.

R Hardie1, L King, R Fraser, M Reid.   

Abstract

BACKGROUND: Patients with sickle cell disease (SCD) are susceptible to bacterial infections, especially those caused by encapsulated organisms such as Streptococcus pneumoniae which is an important cause of morbidity and mortality in early childhood. Preventive measures such as penicillin prophylaxis and immunisation are therefore required. Although penicillin is the mainstay of prophylaxis, pneumococcal vaccination is also important for defence against invasive pneumococcal disease (IPD). AIM: To determine the prevalence of pneumococcal polysaccharide vaccination among patients with SCD diagnosed by newborn screening, and the incidence of IPD in this group of patients.
METHODS: In this retrospective study, data were obtained from the pneumococcal polysaccharide vaccine (PPV) log books and the electronic clinic database. Patients' dockets were searched to confirm their vaccine status if they were over 4 years of age and PPV data had not been found by the above methods. Episodes of invasive pneumococcal disease (sepsis or meningitis) were obtained from the clinic database. Data were analysed using STATA version 9.
RESULTS: Ninety-one per cent of participating patients in the study population who were eligible for PPV had been appropriately immunised. Also, 94.8% of patients with a severe form of SCD had appropriately received PPV. The incidence rate of IPD was 480/100,000 person years in the study population and 160/100,000 person years in patients over 4 years of age.
CONCLUSION: The high prevalence of PPV administration in children with SCD diagnosed by newborn screening had a significant impact on the incidence of IPD with improved patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19689861     DOI: 10.1179/027249309X12467994693851

Source DB:  PubMed          Journal:  Ann Trop Paediatr        ISSN: 0272-4936


  6 in total

1.  The Jamaican historical experience of the impact of educational interventions on sickle cell disease child mortality.

Authors:  Scott D Grosse; Hani K Atrash; Isaac Odame; Djesika Amendah; Frédéric B Piel; Thomas N Williams
Journal:  Am J Prev Med       Date:  2012-06       Impact factor: 5.043

2.  Current sickle cell disease management practices in Nigeria.

Authors:  N Galadanci; B J Wudil; T M Balogun; G O Ogunrinde; A Akinsulie; F Hasan-Hanga; A S Mohammed; M O Kehinde; J A Olaniyi; I N Diaku-Akinwumi; B J Brown; S Adeleke; O E Nnodu; I Emodi; S Ahmed; A O Osegbue; N Akinola; H I O Opara; S A Adegoke; J Aneke; A D Adekile
Journal:  Int Health       Date:  2013-10-10       Impact factor: 2.473

3.  Newborn screening for sickle cell disease in Jamaica: a review - past, present and future.

Authors:  L King; J Knight-Madden; M Reid
Journal:  West Indian Med J       Date:  2014-04-11       Impact factor: 0.171

4.  Socioeconomic and demographic characteristics of sickle cell disease patients from a low-income region of northeastern Brazil.

Authors:  Thales Allyrio Araújo de Medeiros Fernandes; Tereza Maria Dantas de Medeiros; Jayra Juliana Paiva Alves; Christiane Medeiros Bezerra; José Veríssimo Fernandes; Édvis Santos Soares Serafim; Maria Zélia Fernandes; Maria de Fatima Sonati
Journal:  Rev Bras Hematol Hemoter       Date:  2015-04-14

5.  Causes of death and early life determinants of survival in homozygous sickle cell disease: The Jamaican cohort study from birth.

Authors:  Graham R Serjeant; Nicki Chin; Monika R Asnani; Beryl E Serjeant; Karlene P Mason; Ian R Hambleton; Jennifer M Knight-Madden
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

Review 6.  Gaps in knowledge about the vaccine coverage of immunocompromised children: a scoping review.

Authors:  Shannon E MacDonald; Airlie Palichuk; Linda Slater; Hailey Tripp; Laura Reifferscheid; Catherine Burton
Journal:  Hum Vaccin Immunother       Date:  2021-07-16       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.